Equities analysts forecast that Myovant Sciences Ltd (NYSE:MYOV) will post earnings of ($1.03) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Myovant Sciences’ earnings, with estimates ranging from ($1.08) to ($0.98). Myovant Sciences posted earnings of ($0.81) per share in the same quarter last year, which indicates a negative year over year growth rate of 27.2%. The business is expected to report its next earnings report on Thursday, June 6th.

According to Zacks, analysts expect that Myovant Sciences will report full year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.07) to ($3.92). For the next year, analysts expect that the business will post earnings of ($3.90) per share, with EPS estimates ranging from ($4.39) to ($3.51). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last announced its quarterly earnings results on Thursday, February 7th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.06).

A number of analysts have weighed in on MYOV shares. Citigroup reduced their price target on Myovant Sciences from $44.00 to $42.00 and set a “buy” rating for the company in a research report on Monday, November 19th. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research report on Friday, November 9th. ValuEngine raised Myovant Sciences from a “hold” rating to a “buy” rating in a research report on Monday, January 7th. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Finally, Goldman Sachs Group started coverage on Myovant Sciences in a research report on Friday, October 26th. They issued a “neutral” rating and a $25.00 price target for the company. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Myovant Sciences has an average rating of “Buy” and an average target price of $31.00.

In related news, Director Mark Altmeyer purchased 3,500 shares of Myovant Sciences stock in a transaction on Saturday, November 17th. The stock was bought at an average price of $13.38 per share, with a total value of $46,830.00. Following the completion of the transaction, the director now directly owns 3,500 shares of the company’s stock, valued at $46,830. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 3.10% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of MYOV. Renaissance Technologies LLC acquired a new position in shares of Myovant Sciences during the 2nd quarter worth about $297,000. Millennium Management LLC lifted its position in shares of Myovant Sciences by 79.1% during the 2nd quarter. Millennium Management LLC now owns 191,436 shares of the company’s stock worth $4,378,000 after purchasing an additional 84,568 shares during the last quarter. Atria Investments LLC acquired a new position in shares of Myovant Sciences during the 3rd quarter worth about $201,000. Janus Henderson Group PLC lifted its position in shares of Myovant Sciences by 124.8% during the 3rd quarter. Janus Henderson Group PLC now owns 2,525,193 shares of the company’s stock worth $67,044,000 after purchasing an additional 1,401,796 shares during the last quarter. Finally, Opera Trading Capital acquired a new position in shares of Myovant Sciences during the 3rd quarter worth about $117,000. 25.86% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:MYOV opened at $19.57 on Friday. Myovant Sciences has a fifty-two week low of $12.97 and a fifty-two week high of $27.45. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -8.12 and a beta of 0.68. The company has a quick ratio of 3.41, a current ratio of 3.41 and a debt-to-equity ratio of 0.60.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Story: Straddles

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.